459811-04-2

Basic information

• Product Name: 3-(1-ethyl-4,4,6-trimethyl-2-oxo-1,2,3,4-tetrahydro-quinolin-7-yl)-4-trifluoromethoxy-benzaldehyde
• Synonyms: 3-(1-ethyl-4,4,6-trimethyl-2-oxo-1,2,3,4-tetrahydro-quinolin-7-yl)-4-trifluoromethoxy-benzaldehyde
• CAS NO: 459811-04-2
• Molecular Weight: 405.417
• Mol File: 459811-04-2.mol

Chemical Properties

• CAS DataBase Reference: 3-(1-ethyl-4,4,6-trimethyl-2-oxo-1,2,3,4-tetrahydro-quinolin-7-yl)-4-trifluoromethoxy-benzaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(1-ethyl-4,4,6-trimethyl-2-oxo-1,2,3,4-tetrahydro-quinolin-7-yl)-4-trifluoromethoxy-benzaldehyde(459811-04-2)
• EPA Substance Registry System: 3-(1-ethyl-4,4,6-trimethyl-2-oxo-1,2,3,4-tetrahydro-quinolin-7-yl)-4-trifluoromethoxy-benzaldehyde(459811-04-2)

Safety Data

• Hazardous Substances Data: 459811-04-2(Hazardous Substances Data)

Upstream product

• 459811-03-1 7-bromo-1-ethyl-4,4,6-trimethyl-3,4-dihydro-1H-quinoline-2-one 
• 459810-97-0 3-formyl-6-trifluoromethoxy-1-phenyl boronic acid 
• 459811-02-0 7-bromo-4,4,6-trimethyl-3,4-dihydro-1H-quinoline-2-one 
• 181122-00-9 3,4-dihydro-4,4,6-trimethyl-2(1H)-quinolinone 

Downstream Products

• 932367-99-2 C₂₈H₃₂F₃NO₄ 
• 932367-36-7 3-[3-(1-ethyl-4,4,6-trimethyl-2-oxo-1,2,3,4-tetrahydro-qiuinolin-7-yl)-4-trifluoromethoxy-phenyl]-acrylic acid 

Relevant articles and documents

RXR-LXR heterodimer modulators for the potential treatment of dyslipidemia

A number of RXR agonists were synthesized and screened in functional assays. The synthesis and the structure-activity relationship (SAR) within the series of compounds will be presented. Some in vivo data in rodent models for dyslipidemia and diabetes wil

DIHYDRO-[1H]-QUINOLIN-2-ONE DERIVATIVES AS RXR AGONISTS FOR THE TREATMENT OF DYSLIPIDEMIA, HYPERCHOLESTEROLEMIA AND DIABETES

The present invention relates to compounds of Formula (I), methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating RXR mediated disorders. More particularly, the compounds of the present invention are RX

N-substituted heterocycles for the treatment of hypercholesteremia, dyslipidemia and other metabolic disorders; cancer, and other diseases

The present invention relates to certain compounds of Formula (I) which can be useful in the treatment of diseases, such as, cancer, metabolic disorders, Type 2 Diabetes, dyslipidemia and/or hyperchloesterolemia:

RXR activating molecules

Disclosed are molecules that activate an RXR receptor, wherein the molecule comprises an RXR binding portion which binds the RXR receptor and comprises a side pocket contacting residue which contacts a side-pocket 1 of an RXR receptor.